EFFICACY & SUCCESS RATE OF SILODOSIN, ALFUZOSIN & TAMSULOSIN IN CATHETER-FREE TRIALS AFTER ACUTE URINARY RETENTION CAUSED BY BPH
Main Article Content
Keywords
Acute urinary retention, alfuzosin, silodosin, tamsulosin, BPH
Abstract
Introduction: Acute urinary retention is the incapacity to adequately pass the urine and it has sudden painful onset. This study aims to assess the efficacy of silodosin, alfuzosin and tamsulosin in catheter-free trials after AUR caused by BPH, and also to evaluate the factors that affect the success rate of trial without catheter (TWOC)
Methodology: This randomized control trial was conducted at a Tertiary Care Hospital from Jan to Jun 2023. 84 Patients suffering from acute urinary retention secondary to BPH were enrolled in the study having age was between 40 to 82 years, all of them had acute urinary retention with enlarged prostate (>20 g). Patients were divided into 3 groups Group A tamsulosin; B silodosin and Group C alfuzosin respectively. It was also recorded whether TWOC was successful or unsuccessful. Peak flow rate was recorded by uroflowmetry. Further IPSS was recorded after successful TWOC and follow-up visits were planned. All those patients with followed after 2 weeks who had a successful and efficient TWOC and the IPSS was recorded.
Results: 65 patients had successful TWOC, while 56-80 patients had 19 patients with Grade 1 or Grade 2 or Grade 3 TWOC. The overall success of trial without catheter (TWOC) was 61.90% (52 out of 84).
Conclusion: BPH-induced acute urinary retention (AUR) patients can benefit from alfuzosin, silodosin, and tamsulosin, with IPSS improvement after 2 months. All patients should be treated with selective alpha-blockers for efficacy.
References
2. Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis [Internet]. 2004 [cited 2023 May 5];7(1):32–7. Available from: https://www.nature.com/articles/4500700
3. Gabr AH, Abdelatif A, Sharkawy MSE, Ismail AH, Batnanonuy AE, Eissawy MG, et al. Benign prostatic hyperplasia morphological parameters for assessing risk of acute urinary retention. Afr J Urol [Internet]. 2022;28(1). Available from: http://dx.doi.org/10.1186/s12301-022-00294-7
4. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol [Internet]. 1995 [cited 2023 May 5];288(2):201–7. Available from: https://pubmed.ncbi.nlm.nih.gov/7536677/
5. https://www.researchregistry.com/browse-the-registry#home/registrationdetails/64bc4375600e9c0026da6067/
6. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol [Internet]. 2003 [cited 2023 May 15];170(2 Pt 1):530–47. Available from: https://pubmed.ncbi.nlm.nih.gov/12853821/
7. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med [Internet]. 1996 [cited 2023 May 15];335(8):533–9. Available from: https://pubmed.ncbi.nlm.nih.gov/8684407/
8. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol [Internet]. 1995 [cited 2023 May 15];288(2):201–7. Available from: https://pubmed.ncbi.nlm.nih.gov/7536677/
9. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol [Internet]. 1998 [cited 2023 May 15];160(5):1701–6. Available from: https://pubmed.ncbi.nlm.nih.gov/9783935/
10. McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol [Internet]. 2006;175(1):35–42. Available from: https://www.sciencedirect.com/science/article/pii/S0022534705000327
11. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int [Internet]. 2005 [cited 2023 May 15];95(3):354–7. Available from: https://pubmed.ncbi.nlm.nih.gov/15679793/
12. Maldonado-Ávila M, Manzanilla-García HA, Sierra-Ramírez JA, Carrillo-Ruiz JD, González-Valle JC, Rosas-Nava E, et al. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth. Int Urol Nephrol [Internet]. 2014 [cited 2023 May 15];46(4):687–90. Available from: https://pubmed.ncbi.nlm.nih.gov/24061764/
13. Kumar S, Tiwari DP, Ganesamoni R, Singh SK. Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology [Internet]. 2013 [cited 2023 May 15];82(1):171–5. Available from: https://pubmed.ncbi.nlm.nih.gov/23561712/
14. Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study. Cent European J Urol [Internet]. 2017 [cited 2023 May 15];70(3):259–63. Available from: https://pubmed.ncbi.nlm.nih.gov/29104788/
15. Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, Hong SJ, El Khalid S, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia: MANAGEMENT OF ACUTE URINARY RETENTION ASSOCIATED WITH BPH. BJU Int [Internet]. 2012 [cited 2023 May 15];109(1):88–95. Available from: http://dx.doi.org/10.1111/j.1464-410X.2011.10430.x
16. Roehrborn CG. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol. 2009 Autumn;11(Suppl 1):S1-8.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Falak Naz
KRL Hospital, Islamabad Pakistan
Muhammad Rizwan Umer
Sargodha Medical college, Sargodha Pakistan
Muddasir Reyaz Hasan
Northwick Park Hospital
Abubakar Nazir
King Edward Medical university, Lahore Pakistan
Hassan Mumtaz
Health Services Academy, Islamabad Pakistan